https://sciex.com/content/SCIEX/na/us/en


Break the routine: SCIEX OS-MQ improves your quantitation workflows

Sep 13, 2018 | Blogs, Software, Technology | 0 comments

Advances in today’s technology have resulted in a need for higher and faster sample throughput, with increasing number of measured analytes per sample. The new SCIEX OS-MQ software breaks the routine and takes quantitation workflows to a new level. 

Key features include:

  • AutoPeak integration algorithm
  • Automatic outlier removal algorithm
  • Standard addition

Featuring a sleek, intuitive user interface combined with the peak integration algorithm, which allows you to automatically remove outliers from a calibration curve, and includes new tools for flagging and filtering results. Built from the software you already know and trust, these new features and more make data processing and review more streamlined and efficient than ever before, quick to learn and simple to master. The new SCIEX OS 1.4 was designed to support 21 CFR Part 11 Compliance, providing tools such as the incorporation of electronic audit trails, electronic signatures, and detailed security configurations. For those upgrading to SCIEX OS-MQ, a major benefit is the Explorer workspace, which provides the functionality for manual investigation of data similar to PeakView Software. With next-generation SCIEX OS-MQ software, you can be confident that you will achieve accurate and reliable results that address your laboratory requirements and increase overall laboratory productivity.

Read the latest tech note on how SCIEX is Improving Routine Quantitation Workflows in SCIEX OS-MQ.For more questions on upgrading, get in touch with a software specialist today >

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial